Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Ethnopharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1652203

Prescription of EPs 7630 is associated with short-and long-term benefits in acute bronchitis: a real-world data analysis

Provisionally accepted
Adrian GillissenAdrian Gillissen1Thorsten ReinekeThorsten Reineke2Martin BurkartMartin Burkart3Petra FunkPetra Funk2Charles Christian AdarkwahCharles Christian Adarkwah4Karel KostevKarel Kostev5*
  • 1Department of Pulmonary and Intensive Care Medicine, Klinikum Stuttgart Katharinenhospital, Stuttgart, Germany
  • 2Research & Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
  • 3Global Medical Affairs, Dr Schwabe Holding SE & Co KG, Karlsruhe, Germany
  • 4Institute of General Practice, Philipps-University Marburg, Marburg, Germany
  • 5Epidemiology, IQVIA, Frankfurt, Germany

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Introduction: Acute bronchitis is caused by an infection of the lower respiratory tract, resulting in considerable distress of patients and substantial economic costs due to lost workdays. Although acute bronchitis is mostly caused by viruses, antibiotics are frequently used. The aim of this study was to evaluate whether a prescription of EPs 7630 for patients with acute bronchitis is associated with a lower recurrence rate of the disease or fewer complications, a reduced need for antibiotic therapy, or fewer lost workdays.Methods: A retrospective analysis was conducted using the IQVIA™ Disease Analyzer database, which contains information from nearly 3,000 office-based physicians, representing around 3-5% of all German practices. We analyzed the rates of recurrence of acute bronchitis, antibiotic prescription, duration of sick leave, and incidence of complications (pneumonia, chronic bronchitis) with regard to their association with prescriptions of EPs 7630, ambroxol, acetylcysteine, or antibiotics for acute bronchitis.

Keywords: EPs ® 7630, phytopharmaceuticals, Acute bronchitis, Cough, antibiotics, Ambroxol, Acetylcysteine, population-based analysis

Received: 23 Jun 2025; Accepted: 08 Aug 2025.

Copyright: © 2025 Gillissen, Reineke, Burkart, Funk, Adarkwah and Kostev. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Karel Kostev, Epidemiology, IQVIA, Frankfurt, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material